211 related articles for article (PubMed ID: 34677594)
21. Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety.
Merola D; Schneeweiss S; Sreedhara SK; Zabotka LE; Quinto K; Concato J; Wang SV
JNCI Cancer Spectr; 2022 Aug; 6(4):. PubMed ID: 35947646
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
de la Rosette J; Davis R; Frankel D; Kold Olesen T
Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
[TBL] [Abstract][Full Text] [Related]
23. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.
Lee D; Porter J; Gladwell D; Brereton N; Nielsen SK
J Med Econ; 2014 Apr; 17(4):233-47. PubMed ID: 24568188
[TBL] [Abstract][Full Text] [Related]
24. Degarelix.
Frampton JE; Lyseng-Williamson KA
Drugs; 2009 Oct; 69(14):1967-76. PubMed ID: 19747011
[TBL] [Abstract][Full Text] [Related]
25. Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide.
Iversen P; Karup C; van der Meulen E; Tankó LB; Huhtaniemi I
Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):184-90. PubMed ID: 21445092
[TBL] [Abstract][Full Text] [Related]
26. Comparing Cardiovascular Outcomes With Degarelix or Leuprolide as Prostate Cancer Therapy-Applying Real-world Data to Clinical Trial Emulation.
Narayan V
JAMA Netw Open; 2021 Oct; 4(10):e2131429. PubMed ID: 34677599
[No Abstract] [Full Text] [Related]
27. Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.
Sawazaki H; Araki D; Kitamura Y; Yagi K
World J Urol; 2020 Jun; 38(6):1465-1471. PubMed ID: 31482294
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.
Klotz L
Expert Opin Drug Metab Toxicol; 2015; 11(11):1795-802. PubMed ID: 26513436
[TBL] [Abstract][Full Text] [Related]
29. Does Exist a Differential Impact of Degarelix
Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
[TBL] [Abstract][Full Text] [Related]
30. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
[TBL] [Abstract][Full Text] [Related]
31. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
32. Letter by Ng et al Regarding Article, "Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial".
Ng CF; Teoh JYC; Chiu PKF
Circulation; 2022 Mar; 145(12):e773-e774. PubMed ID: 35312383
[No Abstract] [Full Text] [Related]
33. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.
Smith MR; Klotz L; van der Meulen E; Colli E; Tankó LB
J Urol; 2011 Nov; 186(5):1835-42. PubMed ID: 21944083
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
[TBL] [Abstract][Full Text] [Related]
35. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
Van Poppel H; Klotz L
Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
[TBL] [Abstract][Full Text] [Related]
36. Re: Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomized Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists.
Irani J
Eur Urol; 2015 Aug; 68(2):339. PubMed ID: 26149730
[No Abstract] [Full Text] [Related]
37. GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.
Cucchiara V; Yang JC; Liu C; Adomat HH; Tomlinson Guns ES; Gleave ME; Gao AC; Evans CP
Mol Cancer Ther; 2019 Oct; 18(10):1811-1821. PubMed ID: 31341032
[TBL] [Abstract][Full Text] [Related]
38. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
Yannucci J; Manola J; Garnick MB; Bhat G; Bubley GJ
J Urol; 2006 Aug; 176(2):520-5. PubMed ID: 16813881
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Lu L; Peters J; Roome C; Stein K
BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
[TBL] [Abstract][Full Text] [Related]
40. Risks, benefits, and approaches to hormonal blockade in prostate cancer. Highlights from the European Association of Urology Meeting, March 20-24, 2015, Madrid, Spain.
Barkin J
Can J Urol; 2015 Jun; 22(3):7847-52. PubMed ID: 26068639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
